Pazopanib is a UGT1A1 inhibitor and especially patients with Gilbert syndrome, caused by a polymorphism in UGT1A1, have an increased risk of hyperbilirubinemia with the use of pazopanib. The gene discussed is UGT1A1; the disease is Hyperbilirubinemia.